Novo Nordisk A/S

For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.

Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

During 3Q16, Novo Nordisk’s (NVO) net sales rose 2.8% to 27.5 billion Danish kroner from 26.8 billion Danish kroner in 3Q15.

During 1Q16, NVO generated ~77% of its total revenue from its diabetes portfolio. New generation insulin includes sales from Tresiba, Xultophy, and Ryzodeg.

Pfizer reported EPS of $0.67 on revenue of $13.0 billion in 1Q16 against the estimated $0.56 on revenue of $12.1 billion in 1Q16.

After the announcement of Novo Nordisk’s earnings for 4Q15 and fiscal 2015, the stock tumbled by ~6%.

AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.

Eurozone consumer confidence is steady in June despite the ongoing debt crisis in Greece.

Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins.

With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

Novo’s (NVO) Biopharmaceuticals segment rose 5.2 billion Danish kroner during 3Q16.

Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

Biogen’s hemophilia drugs, Alprolix and Eloctate, continued to capture market share in 1Q16.

Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.

The Norwegian krone appreciated against the US dollar on October 9, 2015, as a result of positive inflation data.

Novo Nordisk (NVO) operates in two major segments: diabetes and obesity care and biopharmaceuticals. Diabetes care has been Novo’s major business area.

Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

The Danish krone fell against the US dollar on November 10, 2015. The inflation figures for October were below the expectations.

In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

On June 25, Sanofi (SNY) announced positive results for BRIGHT, a study comparing Sanofi’s Toujeo with Novo Nordisk’s (NVO) Tresiba (degludec).

The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

For investors interested in international mutual funds, the next step is to evaluate the investment style, as well as risk and return metrics like the Sharpe ratio and standard deviation.

In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.

Wall Street analysts estimate that Novo Nordisk (NVO) stock will increase 21.7% over the next 12 months.

The Swedish krona depreciated against the US dollar by more than 1% on December 10, 2015, as inflation levels released below estimates for November.

Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.

GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

Novo’s (NVO) biopharmaceuticals segment sales grew by 6% on a reported basis to amount to 11.8 billion Danish kroner during 1H16.

Of the five analysts covering SNY stock on June 27, two recommended “strong buy,” and three recommended “hold.”

In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.

In October, Pfizer announced that it’s reviewing strategic alternatives, including full or partial separation through sale or a spin-off of its consumer healthcare business.

Danish company Novo Nordisk (NVO) released earnings for 3Q16 on October 28, 2016.

At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018.

Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY growth in local currencies in the first half of 2018.

GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, a ~2% YoY growth.

Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.

Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.

Sandoz, the generics arm of Novartis (NVS), reported nearly flat revenues at ~$2.46 billion during Q2 2018.

Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

In June, Novo Nordisk presented the post hoc analysis of the SUSTAIN 7 trial.

Novo Nordisk’s human insulin generated revenues of 2.37 billion Danish kroner in Q1 2018, compared with 2.5 billion Danish kroner in Q1 2017, reflecting an ~6.0% YoY decline.

In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial.

Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.

The healthcare industry has an average dividend yield of 1.9%.

Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1.

GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products.

In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner.

In 4Q17, Novo Nordisk’s (NVO) modern insulins generated revenues of 10.4 billion Danish kroner.

Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

In fiscal 2017, Novo Nordisk’s (NVO) Xultophy had revenues of 729 million Danish kroner compared to 207 million Danish kroner in 2016.

In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

AstraZeneca (AZN) reported 2% growth in operating revenues to ~$5.8 billion during 4Q17 as compared to the revenues of ~$5.6 billion during 4Q16.

Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.

In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017.

Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.

Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18.

In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.

Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies.

According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.

According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes.

On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1.

In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis.

In 4Q17, Sanofi reported earnings per share of 1.06 euros on revenues of 8.7 billion euros.

In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.

According to IQVIA, glucagon-like peptide products currently account for only a 12% share of the global diabetes care market by value.

Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

Flat revenue performance In its 4Q17 earnings conference call, Novo Nordisk (NVO) has projected sales to be 2%–5% higher YoY (year-over-year) in 2018 in local currency. However, the company also anticipates a seven-percentage-point impact due to unfavorable currency fluctuations, which could impact its revenue growth rate. The company accounts for 27% of the global diabetes care market and […]

Novo Nordisk (NVO) reported sales of ~112 billion Danish kroner in fiscal 2017.

On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.

Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17, representing 5.0% growth in revenues compared to ~$12.3 billion in 4Q16.

On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.

For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.

Sandoz’s positive revenue growth in 4Q17 is expected to be driven by strong sales in European markets and the rest of the world (excluding the US).

The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.